الصفحة 1
الصفحة 1
Medical Decisions, Estrogen and Aging
This book is unique in that it integrates core findings from within the Decision Sciences and Evidence Based Medicine in light of the research that has been done on HT. Medical Decisions, Estrogen and Aging integrates the various components that go into medical decision making in the context of understanding the dilemmas that surround HT. Therefore this book is intended for both specialists and generalists in the field, and it is ideally suited for use by graduate and medical students, medical health care professionals, behavioral scientists, medical ethicists, gerontologists, historians of science, and endocrinologists.
Hormone balance for dummies
Hormones are your body's chemical "messengers," the regulators of essential functions like metabolism, reproduction, mood, and growth. But, in our 24/7, hyper-connected modern world, many of us increasingly find ourselves in situations of chronic stress that can imbalance or disrupt our bodies' natural hormonal balance. In Hormone Balance For Dummies, renowned hormone health coach Isabella Mainwaring delivers an accessible and exciting new take on hormonal imbalance. You'll discover why hormone balance is so important for you and contributes to everything from the maintenance of a healthy weight to fertility, mental wellness, and overall health. The author goes beyond diet and lifestyle to offer practical nervous system regulation tips and dive deep on available treatment options for hormonal imbalance
Le cancer du sein = Breast cancer
The reader will find there both a synthetic summary of the current state of knowledge of epidemiology, risk factors and pathological aspects as well as a presentation of the surgical aspects, in particular, of the new approach that constitutes the sentinel node procedure. Radiotherapy, in a practical view, is divided into essential clinical questions. The medical treatment is then discussed according to the different situations encountered on a daily basis. Particular attention is of course paid to recent data both with the contribution of hormone therapy and targeted therapies. Finally, the symptomatic treatments and especially the psychological care of these patients are not forgotten.
Cancer du sein ; Compte rendu cours supérieur francophone de cancérologie, (Saint-Paul-de-Vence 13-15 Janvier 2005) = Breast cancer ; Report on the advanced French-language course in oncology, (Saint-Paul-de-Vence, January 13-15, 2005)
In January 2005, the 9th Cours de Saint-Paul-de-Vence, devoted to Breast Cancer, was dominated by the establishment of "Recommendations for Clinical Practice". The five subjects of these recommendations, such as the management of the axillary cavity, neo-adjuvant treatments, the management of patients whose tumor overexpresses HER2, adjuvant hormone therapy and finally adjuvant chemotherapy have been widely discussed. As in each course, certain essential fields were treated such as organized screening, conventional radiology and MRI, prognostic and predictive factors. Ductal cancers and lobular cancers have been compared in a remarkable way in three papers which were produced by the Saint-Cloud school. Data on in situ cancers have been updated. Finally, advice was given for the use of the various standards, whether local, regional or national.R2, l¹hormonothérapie adjuvante et enfin la chimiothérapie adjuvante ont été largement abordés.
Aromatase Inhibitors
Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen biosynthesis, the reaction which transforms androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the enzyme's trivial name, aromatase). Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced inhibition of the enzyme and therapeutic benefits in patients with breast cancer, they were not particularly potent and lacked specificity. However, second-generation drugs were developed and most recently third-generation inhibitors have evolved which possess remarkable specificity and potency. Initial results from clinical trials suggest that these agents will become the cornerstones of future endocrine therapy.
Aromatase Inhibitors
Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen biosynthesis, the reaction which transforms androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the enzyme's trivial name, aromatase). Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced inhibition of the enzyme and therapeutic benefits in patients with breast cancer, they were not particularly potent and lacked specificity. However, second-generation drugs were developed and most recently third-generation inhibitors have evolved which possess remarkable specificity and potency. Initial results from clinical trials suggest that these agents will become the cornerstones of future endocrine therapy.
